{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:50:12Z","timestamp":1791557412156,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41409-026-02936-8","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:47:47Z","timestamp":1784260067000},"page":"1327-1334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3421-3971","authenticated-orcid":false,"given":"Aditi","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-8233","authenticated-orcid":false,"given":"Razan","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-2226","authenticated-orcid":false,"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":false,"given":"Julio","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4828-4711","authenticated-orcid":false,"given":"Farhad","family":"Khimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Jaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Ghalehsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4636","authenticated-orcid":false,"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bachmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Alejandro","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather","family":"Jim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-8966","authenticated-orcid":false,"given":"Sayeef","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahm H.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-7338","authenticated-orcid":false,"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-6436","authenticated-orcid":false,"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2936_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"2936_CR2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28:735\u201342.","journal-title":"Nat Med"},{"key":"2936_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"2936_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"Abramson","year":"2020","unstructured":"Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2936_CR5","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308.","journal-title":"Lancet"},{"key":"2936_CR6","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, et al. Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024;30:584-e1.","DOI":"10.1016\/j.jtct.2024.01.074"},{"key":"2936_CR7","doi-asserted-by":"publisher","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024;30:77.e1\u2013e15.","journal-title":"Transplant Cell Ther"},{"key":"2936_CR8","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145\u201354.","journal-title":"Nat Med"},{"key":"2936_CR9","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2023-172978","volume":"142","author":"AJ Portuguese","year":"2023","unstructured":"Portuguese AJ, Albittar A, Liang EC, Huang JJ, Hirayama AV, Kimble EL, et al. Lisocabtagene maraleucel versus axicabtagene ciloleucel: efficacy and toxicity in a real-world setting. Blood. 2023;142:2131.","journal-title":"Blood"},{"key":"2936_CR10","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1080\/10428194.2022.2113526","volume":"63","author":"OO Oluwole","year":"2022","unstructured":"Oluwole OO, Chen JMH, Chan K, Patel AR, Jansen JP, Keeping S, et al. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leuk Lymphoma. 2022;63:3052\u201362.","journal-title":"Leuk Lymphoma"},{"key":"2936_CR11","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.1016\/j.jtct.2023.12.249","volume":"30","author":"AJ Portuguese","year":"2024","unstructured":"Portuguese AJ, Albittar A, Huang JJ, Liang EC, Wuliji N, Taheri M, et al. Real-world comparison of lisocabtagene maraleucel (Liso-Cel) and axicabtagene ciloleucel (Axi-Cel): efficacy & toxicity. Transplant Cell Ther. 2024;30:S192.","journal-title":"Transplant Cell Ther"},{"key":"2936_CR12","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137:2621\u201333.","journal-title":"Blood"},{"key":"2936_CR13","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:4898\u2013911.","journal-title":"Blood Adv"},{"key":"2936_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","volume":"5","author":"RG Faramand","year":"2024","unstructured":"Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, et al. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discov. 2024;5:106\u201313.","journal-title":"Blood Cancer Discov"},{"key":"2936_CR15","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141:2430\u201342.","journal-title":"Blood"},{"key":"2936_CR16","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1182\/blood-2023-185117","volume":"142","author":"A Saha","year":"2023","unstructured":"Saha A, Mohty R, Whiting J, Flores K, Kim J, Nishihori T, et al. A novel composite endpoint of toxicity-free, progression-free survival (TPFS) after CD19-directed chimeric antigen receptor T-cell therapy for relapsed\/refractory large B-cell lymphoma. Blood. 2023;142:1776.","journal-title":"Blood"},{"key":"2936_CR17","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1182\/blood-2023-184406","volume":"142","author":"R Mohty","year":"2023","unstructured":"Mohty R, Junmin W, Saha A, Kim J, Nishihori T, De Avila G, et al. A novel composite endpoint of toxicity- and progression-free survival after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma. Blood. 2023;142:3336.","journal-title":"Blood"},{"key":"2936_CR18","doi-asserted-by":"crossref","unstructured":"Mohty R, Chavez J, Gaballa S, Mokhtari S, Faramand R, Saeed H, et al. Outcomes with axicabtagene ciloleucel in relapsed\/refractory follicular lymphoma: pilot study of a novel composite endpoint of toxicity and progression-free survival. [Poster Presentation P090]. The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians \u2013 Poster Session (P001-P708). Bone Marrow Transplant 2023;58(Suppl 1):153\u2013627.","DOI":"10.1038\/s41409-023-02056-7"},{"key":"2936_CR19","unstructured":"Lazaryan A, Araji G, Buhlmann M, Kim J, Ingram N, Bravo\u202fSolarte D, Ghalehsari N. A Novel severe toxicity\u2011free and progression\u2011free survival endpoint after CD19 chimeric antigen receptor T\u2011cell therapy in mantle cell lymphoma. Poster presented at: EBMT\u2013EHA 8th European CAR\u2011T Cell Meeting; Palma de Mallorca, Spain; 2026."},{"key":"2936_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1182\/blood-2025-400","volume":"146","author":"V Bachanova","year":"2025","unstructured":"Bachanova V, Cao Q, Hu M, Gupta S, Perales M-A, Oluwole O, et al. Novel composite end-points toxicity\/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis. Blood. 2025;146:400.","journal-title":"Blood"},{"key":"2936_CR21","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1002\/sim.6205","volume":"33","author":"AJ Sankoh","year":"2014","unstructured":"Sankoh AJ, Li H, D\u2019Agostino SrRB. Use of composite endpoints in clinical trials. Stat Med. 2014;33:4709\u201314.","journal-title":"Stat Med"},{"key":"2936_CR22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333\u20138.","journal-title":"Blood"},{"key":"2936_CR23","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Malki MMA, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"2936_CR24","doi-asserted-by":"crossref","unstructured":"Gomez-Llobell M, Shouval R, Brown S, Accav NG, Devlin S, Corona M, et al. Landmark-Based evaluations of long-term outcomes after CD19 CAR T-cell therapy in large B-cell lymphoma. Transplant Cell Ther. 2026;32:676.e1\u2013676.e14.","DOI":"10.1016\/j.jtct.2026.02.058"},{"key":"2936_CR25","doi-asserted-by":"crossref","unstructured":"Ghobadi A, Anagnostou T, Azzi J, Hamadani M, Logan B, Ahmed S, et al. Impact of complete response on long-term survival in patients with relapsed or refractory large B-cell lymphoma: a center for international blood and marrow transplant research prospective study and systematic literature review\/meta-analysis. Transplant Cell Ther. 2026;32:623.e1\u2013623.e15.","DOI":"10.1016\/j.jtct.2026.01.010"},{"key":"2936_CR26","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315.","journal-title":"Blood"},{"key":"2936_CR27","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315.","journal-title":"Lancet Oncol"},{"key":"2936_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143:404\u201316.","journal-title":"Blood"},{"key":"2936_CR29","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T Consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"2936_CR30","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2019-124750","volume":"134","author":"MC Pasquini","year":"2019","unstructured":"Pasquini MC, Locke FL, Herrera AF, Siddiqi T, Ghobadi A, Komanduri KV, et al. Post-marketing use outcomes of an anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood. 2019;134:764.","journal-title":"Blood"},{"key":"2936_CR31","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4:5607\u201315.","journal-title":"Blood Adv"},{"key":"2936_CR32","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1182\/blood-2019-129107","volume":"134","author":"JR Westin","year":"2019","unstructured":"Westin JR, Tam CS, Borchmann P, Jaeger U, McGuirk JP, Holte H, et al. Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the Juliet trial. Blood. 2019;134:4103.","journal-title":"Blood"},{"key":"2936_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2023000436","volume":"2023","author":"A Mussetti","year":"2023","unstructured":"Mussetti A, Fabbri N, Sureda A. CAR T-cell therapy in aggressive lymphomas\u2014identifying prognostic and predictive markers. Hematology. 2023;2023:357\u201363.","journal-title":"Hematology"},{"key":"2936_CR34","doi-asserted-by":"crossref","unstructured":"Jacobson C, Hemmer MT, Hu ZH, Frank M, Popplewell L, Ahmed N, Lin Y, Best T, Beygi S, Miao H, Fu C, Sun F, Xu H, Pasquini M. S223: Real world early outcomes of axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. Hemasphere. 2023;7(Suppl):e31464ce.","DOI":"10.1097\/01.HS9.0000967804.31464.ce"},{"key":"2936_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40264-025-01538-5","volume":"48","author":"J Renninger","year":"2025","unstructured":"Renninger J, Kurz L, Stein H. Mitigation and management of common toxicities associated with the administration of CAR-T therapies in oncology patients. Drug Saf. 2025;48:719\u201337.","journal-title":"Drug Saf"},{"key":"2936_CR36","first-page":"419","volume":"31","author":"R Shouval","year":"2025","unstructured":"Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, et al. Cytokine Release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma. Transpl Cell Ther. 2025;31:419\u201333.","journal-title":"Transpl Cell Ther"},{"key":"2936_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"2936_CR38","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","volume":"7","author":"V Blumenberg","year":"2023","unstructured":"Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, et al. Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL. Blood Adv. 2023;7:6844\u20139.","journal-title":"Blood Adv"},{"key":"2936_CR39","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"2936_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/blood.2024026586","volume":"146","author":"MJ Frigault","year":"2025","unstructured":"Frigault MJ, Maziarz RT, Park JH, Lazaryan A, Shah NN, Svoboda J, et al. Itacitinib for the prevention of IEC therapy\u2013associated CRS: results from the 2-part phase 2 INCB 39110-211 study. Blood. 2025;146:422\u201336.","journal-title":"Blood"},{"key":"2936_CR41","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135:1650\u201360.","journal-title":"Blood"},{"key":"2936_CR42","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117\u201327.","journal-title":"Blood"},{"key":"2936_CR43","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2023-186225","volume":"142","author":"M Zhang","year":"2023","unstructured":"Zhang M, Hu Y, Wei G, Fu S, Feng J, Hong R, et al. Dasatinib and CAR-T cell therapy for newly diagnosed Ph-positive acute lymphoblastic leukemia in adults. Blood. 2023;142:891.","journal-title":"Blood"},{"key":"2936_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638639","volume":"12","author":"J Khanali","year":"2021","unstructured":"Khanali J, Azangou-Khyavy M, Boroomand-Saboor M, Ghasemi M, Niknejad H. JAK\/STAT-dependent chimeric antigen receptor (CAR) expression: a design benefiting from a dual AND\/OR gate aiming to increase specificity, reduce tumor escape and affect tumor microenvironment. Front Immunol. 2021;12:638639.","journal-title":"Front Immunol"},{"key":"2936_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","volume":"595","author":"N Xu","year":"2022","unstructured":"Xu N, Yang X-F, Xue S-L, Tan J-W, Li M-H, Ye J, et al. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. Biochem Biophys Res Commun. 2022;595:54\u201361.","journal-title":"Biochem Biophys Res Commun"},{"key":"2936_CR46","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021;137:1832\u20135.","journal-title":"Blood"},{"key":"2936_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jclinepi.2020.07.017","volume":"128","author":"LM Palileo-Villanueva","year":"2020","unstructured":"Palileo-Villanueva LM, Dans AL. Composite endpoints. J Clin Epidemiol. 2020;128:157\u20138.","journal-title":"J Clin Epidemiol"},{"key":"2936_CR48","doi-asserted-by":"crossref","unstructured":"Baracaldo-Santamar\u00eda D, Feliciano-Alfonso JE, Ramirez-Grueso R, Rojas-Rodr\u00edguez LC, Dominguez-Dominguez CA, Calderon-Ospina CA. Making sense of composite endpoints in clinical research. J Clin Med. 2023;12:4371.","DOI":"10.3390\/jcm12134371"},{"key":"2936_CR49","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Hill JA, Dahiya S, Jain MD. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med. 2025;31:2132\u201346.","journal-title":"Nat Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02936-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02936-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02936-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:59:40Z","timestamp":1791554380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02936-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2936"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02936-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AS: No competing interests to disclose. JW: No competing interests to disclose. RM: No competing interests to disclose. KF: No competing interests to disclose. JK: No competing interests to disclose. TN: Medexus (speakers bureau participation), Karyopharm and Novartis (personal fees). JC: Kite\/Gilead, Novartis, BMS, GenMab, Genentech, Autolus, Adicet, CRISPR, ADC Therapeutics, Allogene (consulting); GenMab, Merck (research support); Lilly, GenMab (honoraria). SG: No competing interests to disclose. FK: No competing interests to disclose. HL: Sanofi (speakers\u2019 bureau). BS: Incyte, Jazz, Kite, and Servier (research funding); Janssen, Spectrum\/Acrotech, BeiGene, and Gilead Sciences (honoraria); PeproMene, Lilly, Autolus, Deciphera, Century Therapeutics, Jazz, Kite, Precision Biosciences, Amgen, Pfizer, Novartis, BMS, Adaptive Biotechnologies, AstraZeneca, and Takeda (consultant); PeproMene Bio (advisory committee). MD: No competing interests to disclose. M Jaffer: No competing interests to disclose. S Mokhtari: Kite\/Gilead (consultancy). NG: No competing interests to disclose. HE: Sanofi (consultancy), Shoreline Bio (consultancy), Bristol-Myers Squibb (research funding). CB: No competing interests to disclose. JAG: No competing interests to disclose. HJ: SBR Bioscience (consultancy); Kite (research grant). S Mirza: BMS (speakers bureau). BHS: NextCure (scientific advisory board), NCI (research funding). DKH: Bristol-Myers Squibb, Johnson & Johnson, Karyopharm, Kite Pharma, and Adaptive Biotechnologies (research funding); Bristol-Myers Squibb, Johnson & Johnson, Legend Biotech, Pfizer, Kite Pharma\/Gilead Sciences, AstraZeneca, and Karyopharm (consultancy and advisory board). NB: No competing interests to disclose. FP: Novartis (research funding). RF: Kite\/Gilead (honoraria\/advisory board), Autolus (consultancy\/advisory board), Sanofi (consultancy). M Jain: Kite\/Gilead, Johnson & Johnson, and Prime Education (consultancy\/advisory\/honoraria); Kite\/Gilead, Lilly, Incyte (research funding). FL: A2, Adaptive Biotechnologies, Adaptimmune, Allogene, Amgen, AstraZeneca, Bluebird Bio, BMS, Calibr, Caribou, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Miltenyi, Novartis, Sana, Pfizer, Poseida (scientific advisory\/consulting fees); 2SeventyBio, Allogene, BMS, Incyte, Kite Pharma (institutional support); Leukemia & Lymphoma Society Scholar in Clinical Research; National Cancer Institute (research grant); Aptitude Health, ASH, ASTCT, Clinical Care Options Oncology, and Society for Immunotherapy of Cancer (education\/editorial activities); Data Safety Monitoring Board for NCI CAR-T cell therapies; patents held by the institution in the field of cellular immunotherapy (unlicensed). AL: Incyte, Pierre Fabre, Sanofi (consultancy\/honoraria\/scientific advisory board); U.S. Department of Defense (research funding).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Moffitt Cancer Center (approval number: Pro00024557). All methods were performed in accordance with the relevant guidelines and regulations. Given the retrospective nature of the study, a waiver of informed consent and HIPAA authorization was granted by the IRB. No identifiable human images are included in this manuscript.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}